₹78.36
+1.99% today
· 30d +15.07%
as of 2026-09-04
Price · Daily Candles
“LYKALABS Reels: Plunging Profits, Negative EPS Amidst Sluggish Revenue Growth.”
LYKALABS reported a significant net loss of ₹10 Cr for FY2026, marking a 230.28% decline YoY in net profit, alongside an 8.73% drop in annual revenue to ₹128 Cr. The latest quarterly results further underscore challenges with a net loss of ₹8 Cr and negative EPS of -₹2.13, indicating ongoing financial pressures for the Healthcare sector stock.
BULL CASE
+Despite negative fundamentals, LYKALABS has shown recent short-term price resilience with a 1-month return of +4.9% and 1-week return of +1.17%.
+FIIs slightly increased their stake by 0.12% QoQ, holding 0.29% as of March 2026.
+The 3-year revenue CAGR stands at 9.92%, showing historical top-line expansion despite recent annual decline.
+ML models show neutral to weak predictions for EBIT growth across various lookback periods (e.g., EBIT 1-year recent 2-year rank 0.538).
BEAR CASE
−The company recorded a substantial net loss of ₹10 Cr for FY2026, a 230.28% decrease from the previous year.
−Annual revenue for FY2026 declined by 8.73% YoY to ₹128 Cr.
−Quarterly net profit was negative ₹8 Cr with an EPS of -₹2.13, reflecting significant unprofitability.
−The stock is trading 53.1% below its 52-week high of ₹128.78, with a 1-year return of -48.53%.
−Current FCF is negative ₹6 Cr, leading to a negative FCF yield of -2.75%, underscoring cash flow challenges.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹42 Cr
+28.11% YoY
NET PROFIT
₹2 Cr
+105.44% YoY
OPM
11.62%
-1.21pp YoY
EPS
₹0.57
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-2.1% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
LYKALABS, with no P/E and a ROCE of 10.0%, significantly lags peers like CONCORDBIO (P/E 32.06, ROCE 29.73%) and BIOCON (P/E 183.16, ROCE 10.11%) in profitability metrics.
PEERPEROCE %
LYKALABS—10.0
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
41
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
UNDERPERFORMER
20
Valuation
—
—
Growth
DECLINING
26
Profitability
DECENT
58
Technicals
STRONG
70
Risk
ELEVATED
30
Key Stats
P/B
2.11
52W HIGH
₹102.99
OFF HIGH
-23.91%
MKT CAP
₹277 Cr
◉ Active Signals
MACDBullish0.4802
RSI(14)Bullish68.41
⧉ Strategy Fit 🔒